Brought to you by 
Hoth signs term sheet for Zylo's AEA-loaded Z-pods for CLE; later gains NA rights; Zylo regains rights
08 Dec 2021
Executive Summary
Hoth Therapeutics Inc. and Zylo Therapeutics Inc. signed a non-binding term sheet to partner on the development of a treatment for cutaneous lupus erythematosus (CLE), a chronic autoimmune skin disease, using Zylo's Z-pods sustained-release is a topical delivery system (also known as the Patchless Patch), to which Hoth could potentially get a license.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hoth signs term sheet for Zylo's AEA-loaded Z-pods for CLE; later gains NA rights; Zylo regains rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice